Research on the Accessibility of National Medical Insurance Negotiation Drugs from 2016 to 2021——An Empirical Analysis Based on the National Big Data

OBJECTIVE To investigate the availability of national medical insurance negotiation drugs(national negotiated drugs) nationwide, and provide data support for relevant departments to further promote the implementation of national negotiated drugs. METHODS The national negotiated drugs were statistically analyzed 1 059 secondary and tertiary public general hospitals in 30 provincial administrative regions of China during 2016-2021. RESULTS From 2016 to 2021, the general trend of the availability of national negotiated drugs was upward and the availability rate of national negotiated drugs in tertiary general hospitals was significantly higher than that in secondary general hospitals. The average availability rate of Western medicines was significantly higher than Chinese patent medicines(31.60% vs 17.87%). In addition, the availability rate of national negotiated drugs that had been implemented for a long time was comparatively high. In 2021, the medians of the average drug allocation rates of secondary and tertiary public general hospitals in the provinces were 17.35% and 32.93%, respectively. CONCLUSION The availability rate of national negotiated drugs is related to factors such as the level of medical institutions, the length of time for implementation, and the spectrum of diseases to which drugs are adapted. Medical institutions should further implement relevant policies to ensure the availability of negotiation drugs.